Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Designing transformative clinical trials in the cancer genome era.

Sleijfer S, Bogaerts J, Siu LL.

J Clin Oncol. 2013 May 20;31(15):1834-41. doi: 10.1200/JCO.2012.45.3639. Epub 2013 Apr 15. Review.

PMID:
23589555
2.

The use of genomics in clinical trial design.

Simon R.

Clin Cancer Res. 2008 Oct 1;14(19):5984-93. doi: 10.1158/1078-0432.CCR-07-4531. Review.

3.

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.

Workman P.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.

PMID:
12819933
4.

Implementing personalized cancer genomics in clinical trials.

Simon R, Roychowdhury S.

Nat Rev Drug Discov. 2013 May;12(5):358-69. doi: 10.1038/nrd3979. Review.

PMID:
23629504
5.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.

PMID:
22147736
6.

Future of clinical genomics in pediatric oncology.

Janeway KA, Place AE, Kieran MW, Harris MH.

J Clin Oncol. 2013 May 20;31(15):1893-903. doi: 10.1200/JCO.2012.46.8470. Epub 2013 Apr 15. Review.

PMID:
23589558
7.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
8.

NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ Jr, Bentzen SM, Okunieff P, Coleman CN, Dicker AP.

J Natl Cancer Inst. 2013 Jan 2;105(1):11-24. doi: 10.1093/jnci/djs472. Epub 2012 Dec 10.

9.

Impact of tumor sequencing on the use of anticancer drugs.

Thomas F, Desmedt C, Aftimos P, Awada A.

Curr Opin Oncol. 2014 May;26(3):347-56. doi: 10.1097/CCO.0000000000000078. Review.

PMID:
24709974
10.

Genomic medicine frontier in human solid tumors: prospects and challenges.

Dienstmann R, Rodon J, Barretina J, Tabernero J.

J Clin Oncol. 2013 May 20;31(15):1874-84. doi: 10.1200/JCO.2012.45.2268. Epub 2013 Apr 15. Review.

PMID:
23589551
11.

Improving the evaluation of new cancer treatments: challenges and opportunities.

Rothenberg ML, Carbone DP, Johnson DH.

Nat Rev Cancer. 2003 Apr;3(4):303-9. Review.

PMID:
12671669
12.

[Requirements for the development of molecularly defined targeted therapy in oncology].

Schultze JL.

Med Klin (Munich). 2006 Aug 15;101(8):617-23. Review. German.

PMID:
16896568
13.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
14.
15.

From genomic landscapes to personalized cancer management-is there a roadmap?

Swanton C, Caldas C.

Ann N Y Acad Sci. 2010 Oct;1210:34-44. doi: 10.1111/j.1749-6632.2010.05776.x.

PMID:
20973797
16.

[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].

Ludwig WD.

Z Evid Fortbild Qual Gesundhwes. 2012;106(1):11-22. doi: 10.1016/j.zefq.2011.12.001. Epub 2012 Jan 10. Review. German.

PMID:
22325103
17.

New omics information for clinical trial utility in the primary setting.

Damia G, Broggini M, Marsoni S, Venturini S, Generali D.

J Natl Cancer Inst Monogr. 2011;2011(43):128-33. doi: 10.1093/jncimonographs/lgr032.

PMID:
22043059
18.

From darkness to light with biomarkers in early clinical trials of cancer drugs.

Carden CP, Banerji U, Kaye SB, Workman P, de Bono JS.

Clin Pharmacol Ther. 2009 Feb;85(2):131-3. doi: 10.1038/clpt.2008.223. Review.

PMID:
19151637
19.

Cancer diagnostics: decision criteria for marker utilization in the clinic.

Taube SE, Jacobson JW, Lively TG.

Am J Pharmacogenomics. 2005;5(6):357-64. Review.

PMID:
16336001
20.

Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Ang JE, Kaye S, Banerji U.

Curr Drug Targets. 2012 Nov;13(12):1525-34. Review.

Supplemental Content

Support Center